In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Genzyme Seprafilm: Follow-up at 8-12 weeks post-surgery shows that 51% of abdominal surgery patients treated with the bioresorbable membrane do not develop adhesions, according to results of a study presented Oct. 24 at the American College of Surgeons meeting in New Orleans. The success rate compares to a 6% rate for control patients who did not receive the membrane in the 11-center, 183-subject, prospective, randomized, blinded study. Cambridge, Massachusetts-based Genzyme says it plans to submit the data, along with data from a study of gynecologic surgery, in a PMA for Seprafilm...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.